We are live on ! Find out more
NWBO

Northwest Biotherapeutics, Inc. Common stock
NWBO

Delisted

NWBO was delisted on the 16th of December, 2016.

Back to rankings

10 hedge funds and large institutions have $304K invested in Northwest Biotherapeutics, Inc. Common stock in 2024 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 1

0% more funds holding

Funds holding: 10 → 10 (0)

0% more repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 1

17% less capital invested

Capital invested by funds: $365K → $304K (-$61.5K)

Holders
10
Holders Change
–
Holders Change %
0%
% of All Funds
0.14%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
1
Reduced
1
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
MWM
Maripau Wealth Management
Indiana
+$20.5K
2
EFG
Ethos Financial Group
Pennsylvania
+$12K
3
MSAM
Moloney Securities Asset Management
Missouri
+$11.1K
4
AA
AlphaMark Advisors
Kentucky
+$7K

Top Sellers

Rank Fund Capital Flow
1
BCWM
Bartlett & Co Wealth Management
Ohio
-$3.15K
2
WJWM
Williams Jones Wealth Management
New York
-$2.08K
Name Holding Trade Value Shares
Change 		Change in
Stake
MSAM
1
Moloney Securities Asset Management
Missouri
$197K +$11.1K +21,300 +6%
OCG
2
Opus Capital Group
Ohio
$31K – – –
WJWM
3
Williams Jones Wealth Management
New York
$20.8K -$2.08K -4,000 -9%
MWM
4
Maripau Wealth Management
Indiana
$20.5K +$20.5K +39,493 New
EFG
5
Ethos Financial Group
Pennsylvania
$12K +$12K +23,700 New
MCM
6
MAI Capital Management
Ohio
$10.4K – – –
AA
7
AlphaMark Advisors
Kentucky
$7K +$7K +14,007 New
AMG
8
Advisors Management Group
Wisconsin
$5K – – –
BCWM
9
Bartlett & Co Wealth Management
Ohio
– -$3.15K -4,292 Closed

NWBO Hedge Fund Activity: Q1 2024 in Review

10 of the 6,943 institutional investors tracked by Wall St. Rank reported a position in Northwest Biotherapeutics, Inc. Common stock (NWBO) for Q1 2024, worth a combined $304K — down 17% from $365K a quarter earlier.

Buyers outnumbered sellers: 3 funds opened new NWBO positions and 1 closed out — a net gain of 2 holders — while 1 added to existing stakes and 1 trimmed.

The largest buyer was Maripau Wealth Management, opening a new position worth an estimated $20.5K. The largest seller was Bartlett & Co Wealth Management, exiting entirely with an estimated $3.15K sold.

  • 10 institutional investors held Northwest Biotherapeutics, Inc. Common stock (NWBO) as of Q1 2024, unchanged from Q4 2023.
  • Funds reported $304K of Northwest Biotherapeutics, Inc. Common stock stock for Q1 2024, down 17% quarter-over-quarter.
  • 3 funds opened new Northwest Biotherapeutics, Inc. Common stock positions in Q1 2024 and 1 closed out, a net change of +2 holders.
  • The largest Northwest Biotherapeutics, Inc. Common stock buyer in Q1 2024 was Maripau Wealth Management, an estimated $20.5K added.
  • The largest Northwest Biotherapeutics, Inc. Common stock seller in Q1 2024 was Bartlett & Co Wealth Management, an estimated $3.15K sold.

Based on aggregated 13F filings for Q1 2024.